|
|
|
|
|
Mitotane
drug data and news
Mitotane drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Mitotane | ||
| Brand Names/Synonyms | Chlodithane; Khlodithan; Lysodren; Chlodithan; Chloditan; Mitotan; Mitotanum [INN-Latin]; Lysodren | ||
| Indication | For treatment of inoperable adrenocortical tumours; Cushing's syndrome | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Mitotane is an oral chemotherapeutic agent indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotane can best be described as an adrenal cytotoxic agent, although it can cause adrenal inhibition, apparently without cellular destruction. The administration of Mitotane alters the extra-adrenal metabolism of cortisol in man; leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not fall. The drug apparently causes increased formation of 6-B-hydroxyl cortisol. | ||
| Mechanism Of Action | Its biochemical mechanism of action is unknown, although data are available to suggest that the drug modifies the peripheral metabolism of steroids as well as directly suppressing the adrenal cortex. | ||
| Mitotane News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antineoplastic Agents; ATC:L01XX23 | ||
| Absorption | About 40% oral Lysodren is absorbed | ||
| Interactions | Interactions for Mitotane: Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. In addition, Mitotane should be given with caution to patients receiving other drugs susceptible to the influence of hepatic enzyme induction. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene | ||
| Chemical Formula | C14H10Cl4 | ||
| Molecular Weight | 320.04 g/mol | ||
| Smiles String | C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl | ||
| Melting Point | 77 °C | ||
| Water Solubility | 0.1 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 6.372 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic and renal | ||
| Half Life | 18-159 days | ||
| Protein Binding [%] | 6% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Mitotane.html http://www.rxlist.com/cgi/generic2/mitotane.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00494 | ||
| CAS Registry Number | 53-19-0 | ||
| KEGG Compound ID | C07229 | ||
| PubChem ID | SID:148675 | ||
| PharmGKB ID | PA450525 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 463221 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |